<DOC>
	<DOCNO>NCT00447356</DOCNO>
	<brief_summary>This randomized phase III trial study high dose interferon alfa see well work compare observation treat patient stage II stage III melanoma completely remove surgery .</brief_summary>
	<brief_title>High-Dose Interferon Alfa Treating Patients With Stage II StageIII Melanoma</brief_title>
	<detailed_description>Interferon alfa may interfere growth cancer cell . It yet know whether treatment interferon alfa effective observation alone stage II stage III melanoma completely remove surgically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirm primary melanoma cutaneous origin Stage II ( T3 N0 M0 1.54.0mm Breslow depth Clinically negative regional lymph node pathologic status unkown OR Histologically negative regional lymph node Stage III ( T4 N0 M0 ) Greater 4.0mm Breslow depth OR Stage III ( T14 N1 ) One lymph node positive microscopically Patients must meet least 1 follow criterion T2b N0 primary melanoma 1.012.0mm ulceration , node negative T3ab N0 primary melanoma 2.014.0mm without ulceration , node negative T4ab N0 primary melanoma &gt; 4.0mm without ulceration , node negative T1aN1a2a ( microscopic ) primary melanoma thickness microscopically positive lymph node ( number ) Note EORTC patient node negative T2 T3 ineligible Patients positive sentinel node undergo complete lymphadenectomy nodal basin prior study Must complete primary therapy ( wide excision without lymphadenectomy ) randomize study within 84 day wide excision No clinical , radiological/laboratory , pathological evidence incompletely resect melanoma distant metastatic disease No clinically palpable lymphadenopathy Age : 18 Performance Status : ECOG 01 Life expectancy : Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 125,000/mm^3 Hematocrit least 30 % Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST , LDH , Alkaline phosphate great 2 time ULN If lactate dehydrogenase alkaline phosphate normal , contrast enhance CT scan MRI liver require document absence tumor Renal : BUN great 33mg/dl OR Creatinine great 1.8mg/dl Cardiovascular : No history active ischemic heart disease No cerebrovascular disease No congestive heart failure ( New York Heart Association class III IV heart disease ) Biologic Therapy : No prior immunotherapy include tumor vaccine , interferon , interleukin , levamisole , biologic response modifers melanoma Chemotherapy No prior concurrent chemotherapy Endocrine Therapy No concurrent systemic corticosteriods include oral steriods ( i.e. , prednisone , dexamethasone ) , topical steroid cream ointment , steriodcontaining inhaler . Radiotherapy : No Prior concurrent radiotherapy Surgery : See Disease characteristic Other : No concurrent immunosuppressive medication No history invasive melanoma No autoimmune disorder condition immunosuppression No concurrent prior malignancy within past 5 year Cancer situ Lobular carcinoma situ breast Carcinoma situ cervix Atypical melanocytic hyperplasia Clark 1 melanoma situ Basal squamous cell skin cancer No evidence organic brain syndrome significant impairment basal cognitive function psychiatric disorder would preclude study participation No significant medical surgical condition , medication treatment regimen , would interfere study participation . Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>